[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 56, "title": "CEO, President & Executive Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 826674, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 582280, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 655240, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Oxana  Polyakova Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 48, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 50, "title": "Head of Innovation", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 63, "title": "Chief Development Officer", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Owen P. Hughes Jr.", "age": 49, "title": "Executive Director", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.74, "open": 1.81, "dayLow": 1.625, "dayHigh": 1.82, "regularMarketPreviousClose": 1.74, "regularMarketOpen": 1.81, "regularMarketDayLow": 1.625, "regularMarketDayHigh": 1.82, "payoutRatio": 0.0, "beta": 0.499, "forwardPE": -0.8969072, "volume": 285518, "regularMarketVolume": 285518, "averageVolume": 349206, "averageVolume10days": 209640, "averageDailyVolume10Day": 209640, "bid": 1.31, "ask": 2.08, "bidSize": 2, "askSize": 2, "marketCap": 45771216, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 2.0, "allTimeHigh": 17.2, "allTimeLow": 0.85, "priceToSalesTrailing12Months": 9.172588, "fiftyDayAverage": 1.58946, "twoHundredDayAverage": 1.38986, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -3892786, "profitMargins": 0.0, "floatShares": 17565624, "sharesOutstanding": 26305295, "sharesShort": 425851, "sharesShortPriorMonth": 116555, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0162, "heldPercentInsiders": 0.16385001, "heldPercentInstitutions": 0.27543, "shortRatio": 0.88, "shortPercentOfFloat": 0.026700001, "impliedSharesOutstanding": 26305296, "bookValue": 0.482, "priceToBook": 3.6099586, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -23183000, "trailingEps": -0.87, "forwardEps": -1.94, "enterpriseToRevenue": -0.78, "enterpriseToEbitda": 0.183, "52WeekChange": 0.08074534, "SandP52WeekChange": 0.09209216, "quoteType": "EQUITY", "currentPrice": 1.74, "targetHighPrice": 1.4929156, "targetLowPrice": 1.4929156, "targetMeanPrice": 1.4929156, "targetMedianPrice": 1.4929156, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 49664000, "totalCashPerShare": 1.888, "ebitda": -21325000, "totalDebt": 0, "quickRatio": 11.738, "currentRatio": 12.268, "totalRevenue": 4990000, "revenuePerShare": 0.186, "returnOnAssets": -0.19916001, "returnOnEquity": -1.01508, "grossProfits": 4990000, "freeCashflow": -15868375, "operatingCashflow": -30756000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -4.31924, "financialCurrency": "USD", "symbol": "LVTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChange": 0.0, "regularMarketDayRange": "1.625 - 1.82", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 349206, "fiftyTwoWeekLowChange": 0.89, "fiftyTwoWeekLowChangePercent": 1.0470588, "fiftyTwoWeekRange": "0.85 - 2.0", "fiftyTwoWeekHighChange": -0.26, "fiftyTwoWeekHighChangePercent": -0.13, "fiftyTwoWeekChangePercent": 8.074533, "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "corporateActions": [{"header": "Delisting", "message": "LVTX is being delisted effective Nov. 24, 2025", "meta": {"eventType": "DELISTING", "dateEpochMs": 1763960400000}}], "regularMarketTime": 1763672402, "exchange": "NMS", "messageBoardId": "finmb_546792242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.74, "earningsTimestampStart": 1755520200, "earningsTimestampEnd": 1755865800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.87, "epsForward": -1.94, "fiftyDayAverageChange": 0.15054, "fiftyDayAverageChangePercent": 0.09471141, "twoHundredDayAverageChange": 0.35013998, "twoHundredDayAverageChangePercent": 0.25192463, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-03-25", "prevName": "Lava Therapeutics B.V.", "nameChangeDate": "2025-11-21", "cryptoTradeable": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1616765400000, "displayName": "LAVA Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]